title: [The efficiency of antiviral therapy in patients with chronic -hepatitis C infected with hepatitis C  virus recombinants].
abstract: The review gives the data available in the literature in the efficiency of treatment in patients with chronic hepatitis C infected with hepatitis C virus.(HCV) recombinants, by applying various antiviral therapy regimens. The low efficiency of treatment with- pegylated interferons (PEG IFN) + ribavirin (RIB) and sofosburin (SOF) +RIB in this patient group (a sustained virologic response was achieved in 22 and 30.7%, respectively) compared with the efficiency of treatment (87-97 and 83-97%, respectively) inpatients infected with HCV genotype 2 does not allow the 2015 EASL HCV genotype 2 treatment regimens to be used in. such patients. In this connection, subtyping genotype 2 isolates by NS5B sequencing should be introduced into clinical laboratory practice to successfully detect recombinant HCVs and to enhance the efficiency of antiviral therapy.
authors.affiliation: A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia, Moscow, Russia.
authors.forename: N D
authors.initials: ND
authors.lastname: Yushchuk
authors.affiliation: A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia, Moscow, Russia.
authors.forename: O O
authors.initials: OO
authors.lastname: Znoyko
authors.affiliation: A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia, Moscow, Russia.
authors.forename: K R
authors.initials: KR
authors.lastname: Dudina
authors.affiliation: A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia, Moscow, Russia.
authors.forename: A N
authors.initials: AN
authors.lastname: Kozina
authors.affiliation: Pasteur Saint Petersburg Research Institute of Epidemiology and Microbiology, Saint Petersburg, Russia.
authors.forename: O V
authors.initials: OV
authors.lastname: Kalininа
mesh_terms: D000998:Antiviral Agents / Q000145:classification / Q000494:pharmacology*; D004359:Drug Therapy, Combination; D016174:Hepacivirus / Q000187:drug effects / Q000235:genetics; D019698:Hepatitis C, Chronic / Q000188:drug therapy / Q000821:virology; D006801:Humans; D016865:Reassortant Viruses / Q000187:drug effects / Q000235:genetics; D011995:Recombination, Genetic; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents